MedTrace Logo

Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

NCT04064190 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-12-09

No results posted yet for this study

Summary

This is Phase 2, open label, non randomized single arm study to determine whether the administration of vactosertib with durvalumab will provide meaningful increases in the Overall Response Rate (ORR) in patients with urothelial cancers that fail to achieve a response with anti-PD-1/PD-L1 based regimens

Conditions

  • Urothelial Carcinoma Recurrent
  • Advanced Urothelial Carcinoma

Interventions

DRUG

Vactosertib(TEW-7197)/ Durvalumab

Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • MedPacto, Inc.

    lead INDUSTRY

Principal Investigators

  • Lawrence Fong, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2023-12-30
Completion
2024-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064190 on ClinicalTrials.gov